← All trials
NCT05393193
Phase 4Interventional
Studies of FDA-approved drugs to delineate additional information including the drug's risks, benefits, and optimal use.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jul 4, 2022
- Primary completion
- May 31, 2026
- Completion date
- Aug 31, 2026
- First posted
- May 26, 2022
- Last posted
- Jul 7, 2022
- Enrollment
- 900
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Harvard UniversityLead sponsor
- National Institutes of Health (NIH)Collaborator
- Harvard UniversityOverall official - principal investigator
- Harvard UniversityReponsible party - principal investigator
- Ragon Institute of MGH, MIT and HarvardCollaborator
- Botswana Ministry of HealthCollaborator
- Botswana Harvard Aids InstituteCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.